COINS Act
Coverage of COINS Act in the Nexus archive.
- STAT+: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry
Legislators are pushing to expand the COINS Act to include biotechnology, allowing the U.S. government to restrict investments in the Chinese biotech industry. Venture capitalist Julie Grant opposes these restrictions, arguing they would hinder U.S. drug development and harm patients by disrupting decades-long industry interdependencies.
- Moolenaar Calls to Restrict American Investment in China’s Biotechnology Companies
Chairman John Moolenaar of the Select Committee on China urged Treasury Secretary Scott Bessent to add biotechnology to the prohibited technologies list under the COINS Act of 2025. The request follows increased American investment and intellectual property transfers to China’s biotechnology sector, including Bristol Myers Squibb’s $15 billion deal with Hengrui Pharma.